Condition
Diffuse Large B-cell Lymphoma
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 7 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
7 shownA Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced CancersNCT06870487 · 2025-05-08
TERMINATEDA Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerNCT04254107 · 2020-05-29
TERMINATEDA Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesNCT03538028 · 2018-06-18
COMPLETEDRituximab Plus CHOP Chemotherapy for Diffuse Large B-cell LymphomaNCT02660710 · 2016-03-01
COMPLETEDA Long-term Extension Study of PCI-32765 (Ibrutinib)NCT01804686 · 2013-09-09
ACTIVE_NOT_RECRUITINGBMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and HematologyNCT01660776 · 2012-06-07
COMPLETEDAssessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1NCT00968656 · 2009-01-01
COMPLETEDCommon interventions
Leading sponsors
Trial status mix
COMPLETED4
TERMINATED2
ACTIVE_NOT_RECRUITING1
Phase mix
PHASE14
PHASE21
PHASE31
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.